Victory Capital Management Inc. Purchases 10,011 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Victory Capital Management Inc. increased its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 23.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 53,060 shares of the medical instruments supplier’s stock after buying an additional 10,011 shares during the period. Victory Capital Management Inc. owned 0.24% of LeMaitre Vascular worth $4,929,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of LMAT. NBC Securities Inc. boosted its position in shares of LeMaitre Vascular by 73.2% during the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 183 shares in the last quarter. GAMMA Investing LLC boosted its holdings in LeMaitre Vascular by 57.0% in the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after acquiring an additional 199 shares in the last quarter. West Oak Capital LLC bought a new position in LeMaitre Vascular in the second quarter worth approximately $58,000. USA Financial Formulas bought a new stake in shares of LeMaitre Vascular during the third quarter valued at approximately $60,000. Finally, nVerses Capital LLC raised its position in shares of LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after purchasing an additional 200 shares during the period. Institutional investors own 84.64% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on LMAT. JMP Securities lifted their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 target price for the company. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Thursday. Oppenheimer reiterated an “outperform” rating and set a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Finally, Lake Street Capital initiated coverage on LeMaitre Vascular in a research note on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective for the company. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, LeMaitre Vascular has an average rating of “Moderate Buy” and a consensus target price of $94.57.

LeMaitre Vascular Trading Up 2.0 %

NASDAQ LMAT opened at $107.97 on Friday. The firm has a market capitalization of $2.43 billion, a P/E ratio of 57.85, a PEG ratio of 2.54 and a beta of 0.89. The business has a fifty day simple moving average of $93.48 and a 200 day simple moving average of $86.61. LeMaitre Vascular, Inc. has a 12 month low of $51.70 and a 12 month high of $108.09.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.05. The firm had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business’s revenue was up 15.6% compared to the same quarter last year. During the same period last year, the firm posted $0.33 EPS. As a group, sell-side analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be given a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.59%. The ex-dividend date of this dividend is Thursday, November 21st. LeMaitre Vascular’s dividend payout ratio is 34.97%.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the sale, the director now owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.